MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Progressive supranuclear palsy(PSP)"

  • 2024 International Congress

    Nigral Neuroinflammation and Dopaminergic Neurons in PD, MSA and PSP: A Comparative Clinicopathological Study

    E. Backman, M. Gardberg, L. Luntamo, M. Peurla, T. Vahlberg, P. Borghammer, N. Stefanova, G. Wenning, V. Kaasinen (Turku, Finland)

    Objective: To investigate nigral neuroinflammatory markers and dopaminergic neuron counts in parkinsonian disorders, comparing their profiles across conditions. Background: In degenerative parkinsonian disorders, the primary…
  • 2024 International Congress

    Decoding non-IPD Parkinsonism – A Comparative Analysis of Atypical and Secondary Parkinsonism

    M. Acharya (Kharagpur, India)

    Objective: Using precise diagnostic criteria, the single-center observational study aims to evaluate the clinical profiles of non-IPD parkinsonism, specifically identifying crucial clinical clues for discriminating…
  • 2024 International Congress

    ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)

    A-M. Wills, G. Höglinger, L. Mehta, M. Leinders, Y. Wu, J. Timmons, A. Hayden, I. Aiba, A. Antonini, A. Boxer, Y. Compta, J-C. Corvol, A. Lang, H. Morris, P. Svenningsson, H. [email protected], L. Golbe (Boston, USA)

    Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…
  • 2024 International Congress

    Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy

    G. Martí-Andrés, E. Prieto-Azcarate, CA. Espinoza-Vinces, L. van Bommel, S. Meles, M. Riverol, KL. Leenders, J. Arbizu, MR. Luquin-Puido (Pamplona, Spain)

    Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Progressive Supranuclear Palsy (PSP)…
  • 2024 International Congress

    Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis

    B. Wang, H. Wang, W. Luo (Hangzhou, China)

    Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients,  identifing PSP-specific independent metabolic covariate networks. We also…
  • 2024 International Congress

    Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.

    R. Durcan, J. Rowe (Cambridge, United Kingdom)

    Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…
  • 2024 International Congress

    Paraneoplastic neurological syndrome mimicking a progressive supranuclear palsy: a case series

    R. Zouari, F. Nabli, A. Rachdi, D. Ben Mohamed, MZ. Saeid, S. Ben Sassi (Tunis, Tunisia)

    Objective: we describe 2 patients with paraneoplastic parkinsonism mimicking a PSP. Background: Paraneoplastic neurological syndromes (PNS) are broad-spectrum disorders that can affect any part of…
  • 2024 International Congress

    Frequency of Falls as a Presenti̇ng Symptom and Its Effect i̇n Prognosi̇s i̇n Progressi̇ve Supranuclear Palsy

    I. Kamacı, B. Marangozoglu Samanci, B. Zorlu Ucuncuoglu, E. Sahin, B. Bilgin, H. Hanağası (Istanbul, Turkey)

    Objective: We aimed to evaluate frequency of falls as a presenting symptom and its effect on prognosis in PSP patients. Background: Progressive supranuclear palsy is…
  • 2024 International Congress

    Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy

    A. Roy, S. Brahmachari, A. Pantelyat, L. Rosenthal, V. Dawson, T. Dawson (Baltimore, USA)

    Objective: This study aimed to explore cellular inflammatory and autophagic mediators in neuronal exosomes of PD and PSP. Background: Parkinson’s disease (PD) is a common…
  • 2024 International Congress

    Clinical characteristics and Brain atrophy pattern in the prospective multicenter cohort of Progressive Supranuclear Palsy

    S. Lee, R. Kim, B. Jin, H. Kim, EJ. Yoon, YK. Kim, JH. Shin, HJ. Kim, JY. Lee (Seoul, Republic of Korea)

    Objective: This study aims to investigate volumetric brain MRI features, clinical parameters and their correlations in the Study of Comprehensive ANd multimodal marker-based Cohort of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 38
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley